Establishment Labs Announces Leadership Change in a New Era
Establishment Labs Holdings Inc. (NASDAQ: ESTA), renowned for its dedication to enhancing women's health and wellness, has declared an important leadership transition. After two decades serving as Chief Executive Officer (CEO), Juan José Chacón-Quirós will be retiring from his position effective March 1, 2025. The company is positioned for innovative growth under new leadership, as Peter Caldini, currently President of Establishment Labs, steps in as Interim CEO following Mr. Chacón-Quirós's departure.
Continuation and Commitment
Even after his retirement, Mr. Chacón-Quirós will remain actively involved with Establishment Labs as a board member and advisor. His focus will continue on collaborating with the plastic surgeon community to expand the breast aesthetics and reconstruction markets. This commitment signals the company's intent to uphold the standards and advancements that have been achieved over the years, particularly in terms of safety and product innovation.
Chacón-Quirós Reflects on His Legacy
In reflecting on his decision to step down, Mr. Chacón-Quirós noted the transformational journey the company has undertaken since its inception. He expressed pride in how far Establishment Labs has come, particularly through the introduction of the Motiva product line, which has raised safety standards and minimized complications associated with breast implants.
Board's Confidence in New Leadership
The board of directors has expressed deep gratitude for Mr. Chacón-Quirós's contributions, stating, "His tireless work has significantly impacted the aesthetics landscape, women’s lives, and the regions we serve." With Peter Caldini's extensive background in operations and leadership, the board is optimistic about the company's future direction. They highlight a focus on innovation and maintaining a competitive edge in the United States market.
Pete Caldini's Experience and Vision
Peter Caldini joined Establishment Labs in 2024, bringing comprehensive industry experience. Previously, he served in numerous leadership roles, including CEO of Acreage Holdings, Inc. and Regional President at Pfizer Consumer Healthcare. His diverse background equips him to guide the company through its next phase while continuing to address women's unmet needs in breast health.
Strategic Focus on Innovation
Establishment Labs remains dedicated to pioneering innovative solutions. Under the leadership of Mr. Caldini, the company is set to enhance its market standing and push the boundaries of technology in breast aesthetics. The company is committed to making minimally invasive breast augmentations an industry standard, promoting both safety and patient comfort.
Preliminary Revenue Results and Future Outlook
The company recently shared preliminary unaudited fiscal results for 2024, projecting revenues between $166.0 million and $166.5 million. This expected performance is bolstered by the anticipated contributions from Motiva sales, highlighting the ongoing demand for these advanced aesthetic solutions.
The Comprehensive Product Portfolio
Establishment Labs boasts a diverse range of products aimed at improving women's health. Their extensive portfolio includes Milestones in breast health, aesthetics, and reconstruction. With more than four million Motiva devices distributed globally, Establishment Labs continues to set new benchmarks for quality, safety, and patient satisfaction.
About Establishment Labs
Establishment Labs is a forward-thinking medical device company that champions women's health through advanced technology and rigorous scientific research. Its commitment to enhancing breast health is evident in its comprehensive solutions available in over 90 countries. The company's innovative approaches, including Mia Femtech and Preservé technologies, reflect its dedication to improving patient outcomes and experience.
Frequently Asked Questions
What is the main reason for Juan José Chacón-Quirós's retirement?
Juan José Chacón-Quirós has chosen to retire after two decades to focus on advisory roles while continuing his commitment to women's health initiatives.
Who will lead the company after Chacón-Quirós retires?
Peter Caldini, who currently serves as President, will take on the role of Interim CEO after the retirement of Juan José Chacón-Quirós.
What is the expected revenue for Establishment Labs in 2024?
The company anticipates revenues between $166.0 million and $166.5 million for the fiscal year 2024.
How has Establishment Labs impacted breast aesthetics?
Establishment Labs has significantly improved safety and reduced complications in breast aesthetics through its innovative Motiva product line and other technologies.
What are some key products offered by Establishment Labs?
Key products include the Motiva device range, Mia Femtech, Preservé, and GEM, all aimed at enhancing women's health and aesthetic choices.
